The contract development and manufacturing business segment of GenScript has partnered with Korean biotech Selecxine on innovative antibody drug development.
 
According to the agreement, GenScript will be responsible for preclinical pharmacy research and IND filing in Selecxine’s project. This project is based on cytokine-antibody complexes. Compared with classic monoclonal antibody and protein drug, this project provides a new insight into new drug development, according to the company.
 
“We are delighted to reach strategic collaboration with Selecxine in the field of innovative drug development,” said Brian Min, chief executive officer, GenScript BDBU. “In recent years, Korea’s biopharmaceutical industry has grown rapidly. Among outstanding innovative biotech companies in Korea, Selecxine has extensive experience in innovative therapeutics. This collaboration once again demonstrates our superior process development capabilities. We would like to empower more innovative companies like Selecxine in the future to accelerate the development of innovative therapies and new drug approval.”
 
Jun-Young Lee, chief executive officer, Selecxine, said, “I am so glad to have a collaboration with global CDMO GenScript to develop our lead candidate SLC-3010. During last several years, we have experienced the capability of GenScript as global CDMO through successful performance on multiple sub-projects belong to SLC-3010. I believe that the newly updated agreement for closer partnership covering wide range of new medicine development processes from stable cell line development to GMP production of SLC-3010 will lead us to clinical trials. I hope to maintain this great business partnership as growing together for developing better out-comes in this promising field of drug development.”